Investment
Features
FeesSafety
Academy
More
Pluang+

Law firm investigates Marygold sale, questions $2 per share cash offer to shareholders.

Company Fundamentals
29 Sep 2026
PRNewsWire
View Source
Neutral
Law firm investigates Marygold sale, questions $2 per share cash offer to shareholders.

Monteverde & Associates PC, a top-ranked class action law firm, is investigating the sale of The Marygold Companies, Inc. to affiliates of Madison Dearborn Partners. The proposed deal offers Marygold shareholders $2.00 per share in cash. The firm is assessing whether this offer is fair and encourages shareholders to seek more information or legal advice at no cost. This investigation could impact shareholder decisions regarding the sale.

The shareholder alert on The Marygold Companies, Inc. provides context for readers interested in related financial activity. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 30, 2026 01:11 WIB: out of 85 priced Financials-sector US stocks, 22 rose and 60 fell. Notable movers include Western Union Co at USD 5.95 with a 1-day change of -2.78%, American International Group Inc at USD 74.66 with +2.58%, and BlackRock TCP Capital Corp at USD 4.07 with +2.26%.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
1 hour ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
3 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
4 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
4 hours ago
Altrova Health settles C$215K debt by issuing shares, preserving cash and reducing liabilities.

Altrova Health settles C$215K debt by issuing shares, preserving cash and reducing liabilities.

Altrova Health Inc. has settled C$215,000 of outstanding debt by issuing 3,583,333 common shares at a price of C$0.06 per share to three creditors. This debt settlement did not bring in cash but helped reduce the company's liabilities and preserve ca...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App